

Tiotropium bromide (Spiriva[®])

(No. 19/02)

Boehringer Ingelheim

Summary of Recommendation

6 December 2002

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The recommendation is summarised as follows:

ADVICE

Recommended for general use within NHS Scotland for the maintenance treatment of chronic obstructive pulmonary disease (COPD).

RECOMMENDATION

In clinical trials, tiotropium demonstrated superior efficacy to ipratropium and salmeterol in improving lung function (FEV₁). Generally, it has greater efficacy than ipratropium, and similar efficacy to salmeterol in improving dyspnoea, the use of rescue medication, the frequency of COPD exacerbations and hospitalisation due to exacerbations.

Angela Timoney
Vice-Chairperson